| 000 | nam a22 7a 4500 | ||
|---|---|---|---|
| 999 |
_c6638 _d6638 |
||
| 001 | 6460 | ||
| 003 | ES-MaCNC | ||
| 005 | 20240130132923.0 | ||
| 008 | 240124b ||||| |||| 00| 0 eng d | ||
| 020 | _a9781954750104 | ||
| 040 |
_cES-MaCNC _dES-MaCNC |
||
| 245 | 0 | 0 |
_aPharmaceutical Antitrust: _bAn analysis of US and EU Law |
| 260 |
_aNew York _bInstitute de Droit de la Concurrence _c2023 |
||
| 300 |
_a412 p. _b23 cm |
||
| 336 |
_2isbdcontent _aTexto (visual) |
||
| 337 |
_2isbdmedia _asin mediación |
||
| 490 | 0 | _aConcurrences: Competition Law Review | |
| 500 | _aAutores: Editores: Mélanie Thil-Tayara, George Gordon Prólogos: Alden Abbott, Ian S. Forrester Autores: Katherine Helm, Sophie Pele, James Fishkin, Clemens York, Alec Burnside, Rani Habash, Laurence Bary, Shari Ross Lahlou, Gregory Luib, Marion Provost, Steven Bizar | ||
| 520 | _aThe book provides a comprehensive analysis of antitrust law as it relates to the pharmaceutical industry, with a focus on the US and EU legal frameworks. It explores the complex interplay between intellectual property, regulatory, and competition laws in the pharmaceutical sector. The book covers a range of topics, including marketing authorizations, exclusivities, patent acquisition and enforcement, mergers and acquisitions, and collaboration agreements. It offers practical insights and perspectives from experts in the field, including academics, lawyers, and industry professionals. The book aims to provide a useful resource for legal practitioners, academics, and industry professionals who want to understand the unique challenges and complexities of antitrust law in the pharmaceutical industry. The book includes forewords by Alden Abott of George Mason University and Ian S. Forrester KC of the former General Court of the European Union.<br> <br><b>TABLE OF CONTENTS</b><br> <br>Foreword<br> <br>Alden Abbott, George Mason University<br> <br>Foreword<br> <br>Ian S. Forrester KC, General Court of the European Union<br> <br>List of Abbreviations<br> <br>Table of Contents<br> <br>Chapter I<br> <br>Patent and Regulatory Framework<br> <br>Katherine Helm and Sophie Pele<br> <br>Chapter II<br> <br>Applicable Procedural and Legal Antitrust Framework<br> <br>James Fishkin adn Clemens York<br> <br>Chapter III<br> <br>Mergers adn Acquisitions<br> <br>Alec Burnside and Rani Habash<br> <br>Chapter IV<br> <br>Concerted Conduct<br> <br>Gregory Luib and Marion Provost<br> <br>Chapter VI<br> <br>Private enforcement<br> <br>Steven Bizar and Marion Provost<br> | ||
| 650 | 4 |
_95908 _aSector Farmacéutico |
|
| 650 | 4 |
_9203 _aCompetencia |
|
| 650 | 4 |
_9356 _aDerecho de la competencia |
|
| 650 | 4 |
_9589 _aFusiones y adquisiciones |
|
| 653 | 0 | _aAntitrust | |
| 653 | 0 | _aDefensa de la competencia | |
| 653 | 0 | _aProductos farmacéuticos | |
| 653 | 0 | _aMedicamentos | |
| 653 | 0 | _aIndustria farmacéutica | |
| 653 | 0 | _aConcentración de empresas | |
| 653 | 0 | _aControl de concentraciones | |
| 653 | 0 | _aPatentes | |
| 653 | 0 | _aPropiedad intelectual | |
| 653 | 0 | _aPrácticas anticompetitivas | |
| 653 | 0 | _aPrácticas de exclusión | |
| 653 | 0 | _aPrácticas unilaterales | |
| 653 | 0 | _aAcuerdos de colaboración | |
| 700 | 1 |
_aThill-Tayara, Mélanie _eed. lit. _97760 |
|
| 700 | 1 |
_aGordon, George _eed. lit. _97761 |
|
| 700 | 1 |
_aAbbott, Alden _epról. _97762 |
|
| 700 | 1 |
_aForrester, Ian S. _epról. _97763 |
|
| 856 | 4 | 1 |
_uhttps://opac-cnmc.devxercode.es/cgi-bin/koha/opac-retrieve-file.pl?id=862e051b55388b17720c8e569dce4d29 _zVer índice |
| 856 | 4 | 1 |
_uhttps://www.concurrences.com/en/all-books/pharmaceutical-antitrust _zVer ebook |
| 942 |
_2udc _cMON |
||